Latest APG101 Stories
VAL-083 therapy is well tolerated to date; dose limiting toxicity has not been reached after fifth cohort (20mg/m2) VANCOUVER, British Columbia and MENLO PARK, Calif., April 9, 2014 /PRNewswire/
Topline Data Will Be Presented at Biotech Showcase HEIDELBERG, Germany, Jan.
HEIDELBERG, Germany, Jan.
First European Patient In Trial Operated On In June, Profiled In BBC Report BETHESDA, Md., Dec. 30, 2013 /PRNewswire/ -- Northwest Biotherapeutics, Inc.
Results from a clinical trial of a new treatment for glioblastoma suggest that researchers may have found a new approach to treating this most aggressive of brain tumors, as well as a potential new biological marker than can predict the tumor's response to treatment.